Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review

Sensitivity to endocrine therapy of patients with estrogen receptor (ER)-positive metastatic breast cancer and germline BRCA1/2 mutations is not yet fully elucidated. Furthermore, the registration trials of CDK 4/6 inhibitors in combination with endocrine therapy lacked of a pre-specified subgroup a...

Full description

Bibliographic Details
Main Authors: Anna Maria Militello, Teresa Zielli, Daniela Boggiani, Maria Michiara, Nadia Naldi, Beatrice Bortesi, Paola Zanelli, Vera Uliana, Sara Giuliotti, Antonino Musolino
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
BRCA
CDK4/6 inhibitor
breast cancer
estrogen receptor
cyclin D1
endocrine therapy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00759/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00759/full

Similar Items